Richard Lowenthal

So we just decided to stay with them.

Again, low risk.

As you said, they're very high quality products.

And they really are the state of the art in the business of manufacturing these nasal spray devices.

So kind of an easy decision for us at the time.

There are a couple...

manufacturers overseas now, mostly because of generic competition that's coming in with some of the other nasal sprays that are earlier.

So we do know there are some other manufacturers in India and in the European region that can manufacture.

And that's why we're also looking at one of them in the European region for a second supplier so that we're not sole supplied.

Yes.

So we launched NEFI roughly a year ago now, the two milligram first, and then we added in the one milligram a few months back.

i think the launch is going well um of course you know it it's always slow at the beginning with any launch because of insurance coverage and adoption period of doctors to get used to the product we also experienced one thing that was a little bit unanticipated given nefi is a very high volume product but

low revenue per script per prescription.

So you need a lot of prescriptions to make up the market.

And what we found is that when doctors are very busy, they tend to have less time to prescribe new medications.

New medications always take them more time than just a renewal prescription.

So what we believe is one pathway to help with that is we're providing now more

support for prior authorization, so more ways for them to do that, and then more options for the patients as well to get NEFI where they can get it without going to an office visit with their doctor.

So we're working on those types of things to further boost the market share.

And again, over time, as we get into